Menu

Trump Picks National Cancer Institute Director

Ned Sharpless currently leads the cancer center at the University of North Carolina, Chapel Hill.

Jun 12, 2017
Kerry Grens

BRIAN STRICKLAND/LINEBERGER COMPREHENSIVE CANCER CENTER Update (October 18): Sharpless was sworn in as NCI director today.

President Donald Trump has selected Ned Sharpless, a physician in charge of the cancer center at the University of North Carolina, Chapel Hill, to lead the National Cancer Institute (NCI). The nomination received praise from the cancer research community.

Margaret Foti, the chief scientific officer of the American Association for Cancer Research, says in a statement she is “absolutely thrilled” by Trump’s choice. “[Sharpless’s] enthusiasm for innovative scientific methods and ideas, as well as his appreciation for the value and importance of basic research to advancing translational discoveries, will allow the NCI to continue leading the way in programs aimed at preventing disease, improving health, and reducing suffering from cancer, while also helping to maintain America’s edge in the life sciences.”

Sharpless’s group studies cellular senescence in aging and cancer. In particular, he researches the role of the tumor suppressor p16INK4a in melanoma.

Since Harold Varmus stepped down as director of the National Cancer Institute in 2015, Douglas Lowy has filled in as acting director. Varmus, whose lab is based at Weill Cornell Medicine, echoes the praise, telling Science: “From everything I know, this is an excellent choice.”

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.